Barchas Isaac 4
4 · Immunome Inc. · Filed Jul 2, 2026
Research Summary
AI-generated summary of this filing
Immunome (IMNM) Director Isaac Barchas Sells Shares
What Happened
Isaac Barchas, a director (and managing member of related entities), sold a total of 201,050 shares of Immunome common stock in three open‑market dispositions for aggregate proceeds of $4,393,025. The sales were: 101,050 shares on 2026-06-30 at a weighted average price of $21.12 (range $20.83–$21.47) for $2,134,176; 75,665 shares on 2026-07-02 at a weighted average price of $22.35 (range $22.015–$23.015) for $1,691,113; and 24,335 shares on 2026-07-02 at a weighted average price of $23.33 (range $23.03–$23.67) for $567,736. These were sales (not purchases).
Key Details
- Transaction dates and weighted-average prices:
- 2026-06-30 — 101,050 sh @ $21.12 (range $20.83–$21.47) = $2,134,176
- 2026-07-02 — 75,665 sh @ $22.35 (range $22.015–$23.015) = $1,691,113
- 2026-07-02 — 24,335 sh @ $23.33 (range $23.03–$23.67) = $567,736
- Total shares sold: 201,050; total proceeds: $4,393,025.
- Shares owned after transactions: ABHMC (an entity managed by Barchas) owns 308,504 shares. The reporting person disclaims beneficial ownership of the shares held by these entities except to the extent of any pecuniary interest.
- Notable footnotes:
- Sales were automatic under Rule 10b5-1 trading plans adopted by ABHMC II LLC and Arsenal Bridge Venture II‑B LLC on March 31, 2026.
- Some shares sold were by related entities (e.g., 100,000 sold by ABHMC and 1,050 by ABV II‑B as reported).
- Several footnotes explain that certain shares previously received were pro rata distributions in kind (a change in form of ownership) and thus not reportable as Section 16 acquisitions.
- Filing: Form 4 filed 2026-07-02 covering transactions through 2026-06-30/07-02; appears to be filed within the typical 2-business‑day window.
Context
- These were routine sales executed under pre-arranged 10b5-1 plans (not necessarily a contemporaneous personal trading decision). 10b5-1 plans allow scheduled trades and are common for liquidity or diversification.
- Sales are generally less informative about insider sentiment than purchases; no options were exercised and no gifts or awards are reported here.
Insider Transaction Report
Form 4
Immunome Inc.IMNM
Barchas Isaac
Director
Transactions
- Sale
Common Stock
[F1][F2][F3][F4][F5]2026-06-30$21.12/sh−101,050$2,134,176→ 308,504 total(indirect: See footnotes) - Sale
Common Stock
[F1][F6][F7]2026-07-02$22.35/sh−75,665$1,691,113→ 232,839 total(indirect: See footnote) - Sale
Common Stock
[F1][F8][F7]2026-07-02$23.33/sh−24,335$567,736→ 208,504 total(indirect: See footnote)
Holdings
- 103,259
Common Stock
[F9]
Footnotes (9)
- [F1]The reported sale of these shares occurred automatically pursuant to Rule 10b5-1 trading plans adopted by ABHMC II LLC ("ABHMC") and Arsenal Bridge Venture II-B LLC ("ABV II-B"), each on March 31, 2026.
- [F2]The shares were sold as follows: 100,000 shares were sold by ABHMC and 1,050 shares were sold ABV II-B.
- [F3]The weighted average sale price for the transaction report was $21.12, and the range of prices were between $20.83 and $21.47, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F4]The shares of Issuer common stock held by the Reporting Person prior to the transaction reported herein reflect pro rata distributions in kind for no additional consideration, effected by each of Arsenal Bridge Venture II LLC ("ABV II") and ABV II-B to their respective members, including ABHMC, the managing member of ABV II and ABV II-B. The receipt of such shares by the Reporting Person constituted a change in form of ownership and, therefore, was not required to be reported pursuant to Section 16, including Rule 16a-13. Following this transaction, ABHMC owns the remaining 308,504 shares of Issuer common stock.
- [F5]The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC and is a co-founder and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABV II-B. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares.
- [F6]The weighted average sale price for the transaction report was $22.35, and the range of prices were between $22.015 and $23.015, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F7]ABHMC owns the shares of Issuer common stock. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares.
- [F8]The weighted average sale price for the transaction report was $23.33, and the range of prices were between $23.03 and $23.67, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F9]The shares of Issuer common stock held by the Reporting Person prior to the transaction reported herein reflect pro rata distributions in kind for no additional consideration, effected by ABV II to its members of the shares received in such distributions by members, including the Reporting Person. The receipt of such shares by the Reporting Person constituted a change in form of ownership and, therefore, was not required to be reported pursuant to Section 16, including Rule 16a-13.
Signature
/s/ Sandra Stoneman, Attorney-in-Fact|2026-07-02